Table 2 In vivo pharmacokinetic profile of GSK3011724A.

From: Identification of KasA as the cellular target of an anti-tubercular scaffold

Target dose (mg kg−1)

Cmax (ng ml−1)

Cmax/Dose ng ml−1 (mg kg−1)

t max (h)

AUC0- t (ng h ml−1)

DNAUC ng h ml−1 (mg kg−1)

10*

917±279

84.7±21.5

0.25–0.75

1099±152

104±19.1

25

1392±424

63.9±19.4

0.5

2279±581

107±27.3

50

12500±153

250±23.1

0.25–1.0

32549±3009

667±64.2

100

10570±572

120±6.49

0.75–1.0

57179±7559

667±57.2

200

33000±7017

165±35.1

2.0

251437±37054

1272±188

  1. AUC, area under the curve; Cmax, maximum concentration measured; DNAUC, dose-normalized area under the curve.
  2. Pharmacokinetic parameters estimated for GSK3011724A after a single oral gavage administration to female C57BL/6J mice (n=3) at different doses. Mice dosed above 400 mg kg−1 were withdrawn after the second administration of GSK3011724A due to poor clinical status. Standard deviation (s.d.) of the mean is also included.
  3. *Mean and s.d. values calculated from n=3 mice.
Back to article page